

Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

BIO IMAGING TECHNOLOGIES INC  
Form 10QSB  
August 14, 2001

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----  
FORM 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2001  
Commission File No. 1-11182

BIO-IMAGING TECHNOLOGIES, INC.

-----  
(Exact Name of Small Business Issuer as Specified in Its Charter)

Delaware

11-2872047

-----  
(State or Other Jurisdiction of  
Incorporation or Organization)

-----  
(I.R.S. Employer Identification No.)

826 Newtown-Yardley Rd., Newtown, PA 18940

18940

-----  
(Address of Principal Executive Offices)

-----  
(Zip Code)

(267) 757-1360

-----  
(Issuer's Telephone Number,  
Including Area Code)

Check whether the Issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes: X  
-----

No: \_\_\_\_\_

State the number of shares outstanding of each of the Issuer's classes of common stock, as of June 30, 2001:

Class

Number of Shares

-----  
Common Stock, \$.00025 par value

-----  
8,259,212

Transitional Small Business Disclosure Format (check one):

Yes: \_\_\_\_\_

No: X  
-----

BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

	Page
	----
PART I. FINANCIAL INFORMATION.	
Item 1. Financial Statements.....	1
CONSOLIDATED BALANCE SHEETS	
as of June 30, 2001 and	
September 30, 2000 (unaudited).....	2
CONSOLIDATED STATEMENTS OF OPERATIONS	
For the Nine Months Ended	
June 30, 2001 and 2000 (unaudited).....	3
CONSOLIDATED STATEMENTS OF OPERATIONS	
For the Three Months Ended June 30, 2001 and 2000	
(unaudited).....	4
CONSOLIDATED STATEMENTS OF CASH FLOWS	
For the Nine Months Ended June 30, 2001 and 2000	
(unaudited).....	5
NOTES TO CONSOLIDATED FINANCIAL	
STATEMENTS (unaudited).....	6
Item 2. Management's Discussion and Analysis of Financial	
Condition and Results of Operations.....	9
Results of Operations.....	10
Liquidity and Capital Resources.....	14
PART II. OTHER INFORMATION.	
Item 2. Changes in Securities and Use of Proceeds.....	16
Item 6. Exhibits and Reports on Form 8-K.....	16
SIGNATURES .....	17

- i -

PART I. FINANCIAL INFORMATION.

ITEM 1. FINANCIAL STATEMENTS.

Certain information and footnote disclosures required under generally accepted accounting principles have been condensed or omitted from the following

## Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission, although Bio-Imaging Technologies, Inc. (the "Company") believes that such financial disclosures are adequate so that the information presented is not misleading in any material respect. The following consolidated financial statements should be read in conjunction with the year-end consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-KSB for the fiscal year ended September 30, 2000.

The results of operations for the interim periods presented herein are not necessarily indicative of the results to be expected for the entire fiscal year.

-1-

### BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES

#### CONSOLIDATED BALANCE SHEETS

(unaudited)

	June 30, 2001	September 30, 2000
	-----	-----
ASSETS		
Current assets:		
Cash and cash equivalents.....	\$ 147,479	\$ 491,048
Accounts receivable, net.....	2,414,508	1,627,457
Prepaid expenses and other current assets.....	299,467	234,201
	-----	-----
Total current assets.....	2,861,454	2,352,706
Property and equipment, net.....	1,222,850	1,292,344
Other assets .....	244,557	261,762
	-----	-----
Total assets.....	\$ 4,328,861	\$ 3,906,812
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable.....	\$ 513,072	\$ 321,113
Accrued expenses and other current liabilities.....	166,914	229,354
Deferred revenue.....	1,598,387	1,707,681
Current maturities of long-term debt.....	190,505	150,796
	-----	-----
Total current liabilities.....	2,468,878	2,408,944
Long-term debt.....	141,200	164,139
	-----	-----
Total liabilities.....	2,610,078	2,573,083

Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

	-----	-----
Stockholders' equity:		
Preferred stock - \$.00025 par value; authorized 3,000,000 shares, issued and outstanding, 0 shares at June 30, 2001, and 416,667 shares (\$500,000 liquidation preference) at September 30, 2000.....	--	104
Common stock - \$.00025 par value; authorized 18,000,000 shares, issued and outstanding 8,259,212 shares at June 30, 2001 and 7,773,878 shares at September 30, 2000.....	2,065	1,944
Additional paid-in capital.....	9,274,740	9,231,497
Accumulated deficit.....	(7,558,022)	(7,899,816)
	-----	-----
Stockholders' equity.....	1,718,783	1,333,729
	-----	-----
Total liabilities and stockholders' equity.....	\$ 4,328,861	\$ 3,906,812
	=====	=====

See Notes to Consolidated Financial Statements

-2-

BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES

-----  
CONSOLIDATED STATEMENTS OF OPERATIONS  
-----

(unaudited)

	For the Nine Months Ended June 30,	
	2001	2000
	-----	-----
Project revenues.....	\$ 6,160,341	\$ 4,105,911
	-----	-----
Cost and expenses:		
Cost of revenues.....	3,404,374	2,705,862
General and administrative expenses.....	1,115,190	963,965
Sales and marketing expenses.....	1,271,924	1,138,621
	-----	-----
Total cost and expenses.....	5,791,488	4,808,448
	-----	-----
Income (loss) from operations.....	368,853	(702,537)
Interest expense - net.....	(17,059)	(54,831)
	-----	-----

Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

Net income (loss).....	351,794	(757,368)
Dividends on preferred stock.....	10,000	30,000
	-----	-----
Net income (loss) applicable to common stock.....	\$ 341,794	\$ (787,368)
	=====	=====
Basic earnings (loss) per common share.....	\$ 0.04	\$ (0.10)
	=====	=====
Weighted average number of common shares.....	8,199,376	7,773,878
	=====	=====
Diluted earnings (loss) per common share.....	\$ 0.04	\$ (0.10)
	=====	=====
Weighted average number of common shares and dilutive common equivalent shares...	8,383,824	7,773,878
	=====	=====

See Notes to Consolidated Financial Statements

-3-

BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES

-----  
CONSOLIDATED STATEMENTS OF OPERATIONS  
-----

(unaudited)

	For the Three Months Ended June 30,	
	----- 2001 -----	----- 2000 -----
Project revenues.....	\$ 2,252,507	\$ 1,565,412
	-----	-----
Cost and expenses:		
Cost of revenues.....	1,366,958	1,053,363
General and administrative expenses.....	330,895	342,553
Sales and marketing expenses.....	466,628	442,215
	-----	-----
Total cost and expenses.....	2,164,481	1,838,131
	-----	-----

Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

Income (loss) from operations.....	88,026	(272,719)
Interest expense - net.....	(8,123)	(34,475)
	-----	-----
Net income (loss).....	79,903	(307,194)
Dividends on preferred stock.....	--	10,000
	-----	-----
Net income (loss) applicable to common stock.....	\$ 79,903	\$ (317,194)
	=====	=====
Basic earnings (loss) per common share.....	\$ 0.01	\$ (0.04)
	=====	=====
Weighted average number of common shares.....	8,217,234	7,773,878
	=====	=====
Diluted earnings (loss) per common share.....	\$ 0.01	\$ (0.04)
	=====	=====
Weighted average number of common shares and dilutive common equivalent shares.....	8,484,572	7,773,878
	=====	=====

See Notes to Consolidated Financial Statements

-4-

BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	For the Nine Months June 30,	
	-----	
	2001	
	----	
Cash flows from operating activities:		
Net income (loss) .....	\$ 351,794	\$
Adjustments to reconcile net income (loss) to net cash used in operating activities:		
Depreciation and amortization.....	398,138	
Changes in operating assets and liabilities:		
Increase in accounts receivable.....	(787,051)	
Increase in prepaid expenses and other current assets.....	(65,266)	
Decrease (increase) in other assets.....	17,205	
Increase in accounts payable.....	201,959	
Decrease in accrued expenses and other current liabilities.....	(62,440)	
(Decrease) increase in deferred revenue.....	(109,294)	1

Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

Net cash used in operating activities.....	(54,955)	
Cash flows from investing activities:		
Purchases of property and equipment.....	(193,828)	
Net cash used in investing activities.....	(193,828)	
Cash flows from financing activities:		
Payments on equipment lease obligations and notes payable.....	(118,046)	
Dividends paid to preferred stockholders.....	(20,000)	
Proceeds from exercise of warrants and stock options	43,260	
Proceeds from notes payable.....	--	
Net cash (used in) provided by financing activities.....	(94,786)	
Net decrease in cash and cash equivalents.....	(343,569)	
Cash and cash equivalents at beginning of period.....	491,048	
Cash and cash equivalents at end of period.....	\$ 147,479	\$
Supplemental disclosures of cash flow information:		
Cash paid during the year for interest.....	\$ 24,299	\$
Supplemental Schedule of noncash investing and financing activities:		
Equipment purchased under capital lease obligations.....	\$ 134,816	\$

See Notes to Consolidated Financial Statements

-5-

BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 1 - Basis of Presentation:

The financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto

## Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

included in the Company's Annual Report on Form 10-KSB for the year ended September 30, 2000.

In the opinion of the Company's management the accompanying unaudited consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary to present fairly its financial position as of June 30, 2001 and the results of its operations and its cash flows for the nine months ended June 30, 2001 and 2000 and the results of its operations for the three months ended June 30, 2001 and 2000.

Interim results are not necessarily indicative of results for the full fiscal year.

Basic earnings (loss) per common share was calculated based upon the net earnings (loss) available to common stockholders divided by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share for the three months ended June 30, 2001 and nine months ended June 30, 2001 was calculated based upon net earnings available to common stockholders divided by the weighted average number of shares of common stock outstanding during the period, adjusted for dilutive securities using the treasury method. Diluted loss per common share for the three months ended June 30, 2000 and nine months ended June 30, 2000 exclude the impact of convertible preferred stock, options (1,430,775 as of June 30, 2000) and warrants (66,667 as of June 30, 2000) as their inclusion would be antidilutive.

-6-

### BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 1 - Basis of Presentation: (continued)

The computation of basic earnings (loss) per common share and diluted earnings (loss) per common share were as follows:

	Nine Months Ended June 30,		Three Months June 30	
	2001	2000	2001	
Net income (loss).....	\$ 351,794	\$ (757,368)	\$ 79,903	\$
Dividends on preferred stock.....	(10,000)	(30,000)	--	--
Net income (loss) applicable to common stock - basic.....	\$ 341,794	\$ (787,368)	\$ 79,903	\$
Dilutive dividends on preferred stock.....	10,000	--	--	--



Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

Net income (loss) applicable to common stock - diluted.....	\$ 351,794	\$ (787,368)	\$ 79,903	\$
Denominator:				
Weighted average number of common shares.....	8,199,376	7,773,878	8,217,234	
Basic earnings (loss) per common share.....	\$ 0.04	\$ (0.10)	\$ 0.01	\$
Denominator:				
Weighted average number of common shares.....	8,199,376	7,773,878	8,217,234	
Common share equivalents of outstanding stock options and warrants.....	184,448	--	267,338	
Total shares.....	8,383,824	7,773,878	8,484,572	
Diluted earnings (loss) per common share.....	\$ 0.04	\$ (0.10)	\$ 0.01	\$

-7-

BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 2 - Stockholders' Equity:

On January 2, 2001, the Company elected to convert the 416,667 shares of its Series A Convertible Preferred Stock, \$.00025 par value per share (the "Series A Stock"), held of record by Investment Partners of America, L.P. ("IPA") into 416,667 shares of its restricted common stock, \$.00025 par value per share (the "Common Stock"). The shares of Common Stock issued upon conversion of the Series A Stock were issued to the designees of IPA and have certain piggy-back registration rights. The Company has satisfied any and all obligations with respect to cumulative dividends on the Series A Stock. The Company did not receive any consideration for the conversion of the Series A Stock. Subsequent to the conversion, the Company has no issued and outstanding shares of Series A Stock.

During May and June of 2001, the Company issued an aggregate of 66,667 shares of its restricted Common Stock to IPA and its affiliate in connection with the exercise of 66,667 Class C Warrants (the "Class C Warrants") to purchase shares of Common Stock of the Company previously issued to IPA on June

## Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

26, 1996. The Class C Warrants had an exercise price equal to \$.63 per share at the time of exercise, and the Company received \$42,000 as proceeds for the exercise of such warrants by IPA and its affiliate.

The Company has neither paid nor declared dividends on its Common Stock since its inception and does not plan to pay dividends on its Common Stock in the foreseeable future.

### Note 3 - Long-term Debt:

During the nine months ended June 30, 2001, the Company did not assign any accounts receivables under the accounts receivable financing agreement with Silicon Valley Bank. At June 30, 2001, the Company had no borrowings under the accounts receivable financing agreement. In July 2001, the Company assigned accounts receivable of approximately \$212,000 to the Bank. At July 31, 2001, the Company had a payable balance of approximately \$170,000 to the Bank.

### Note 4 - Recently Issued Accounting Standards:

In December 1999, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 101 ("SAB 101"), Revenue Recognition in Financial Statements. SAB 101 provides guidance for revenue recognition under certain circumstances. The accounting and disclosures prescribed by SAB 101 will be effective for the fourth quarter of fiscal year 2001. The Company does not believe that the application of SAB 101 will have a material impact on its financial position or results of operations.

-8-

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

### OVERVIEW

Bio-Imaging Technologies, Inc. ("Bio-Imaging" or the "Company") is a pharmaceutical contract service organization, providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company specializes in assisting its clients in the design and management of the medical-imaging component of clinical trials for all modalities which consist of computerized tomography, magnetic resonance imaging, x-rays, dual energy x-ray absorptiometry, positron emission tomography single photon emission computerized tomography and ultrasound. The Company provides services which include the processing and analysis of medical images and the data-basing and regulatory submission of medical images, quantitative data and text. A new division of the Company, Bio-Imaging ETC, is focused on education, training and certification for medical-imaging equipment, facilities and staff.

The Company's sales cycle (the period from the presentation by the Company to a potential client to the engagement of the Company by such client) is generally twelve months. In addition, the contracts under which the Company performs services typically cover a period of 12 to 36 months and the volume and type of services performed by the Company generally vary during the course of a project. No assurance can be made that the Company's project revenues will remain at levels sufficient to maintain profitability. Project revenues were generated from 51 clients encompassing 97 distinct projects for the nine months

## Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

ended June 30, 2001 as compared to 38 clients encompassing 79 distinct projects for the nine months ended June 30, 2000. This represents an increase of 34.2% in clients and 22.8% in projects for the nine months ended June 30, 2001 as compared to the nine months ended June 30, 2000. The Company's contracted/committed backlog was approximately \$18,500,000 as of June 30, 2001 as compared to approximately \$13,500,000 as of June 30, 2000, an increase of 37.0%. Contracted/committed backlog as of July 31, 2001, was approximately \$18,600,000. Contracted/committed backlog is the amount of revenue that remains to be earned and recognized on signed and agreed to contracts. Such contracts are subject to termination by the Company's clients at any time.

The Company believes that demand for its services and technologies will grow during the long-term as the use of digital technologies for data acquisition and management increases in the radiology and drug development communities. The Company also believes that there is a growing recognition within the bio-pharmaceutical industry regarding the use of an independent centralized core laboratory for analysis of medical-imaging data that is derived from clinical trials and the rigorous regulatory requirements relating to the submission of this data. In addition, the Food and Drug Administration ("FDA") is gaining experience with electronic submissions and is continuing to develop guidelines for computerized submission of data, including medical images. Furthermore, the increased use of digital medical images in clinical trials, especially for important drug classes such as anti-inflammatory, neurologic and oncologic

-9-

therapeutics and diagnostic image agents, generate large amounts of image data that will require processing, analysis, data management and submission services. Due to several factors, including, without limitation, an increase in competition from commercial competitors and academic research centers, there can be no assurance that demand for the Company's services and technologies will grow, sustain growth, or that additional revenue generating opportunities will be realized by the Company.

Certain matters discussed in this Form 10-QSB are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, the Company's statements regarding the demand for the Company's services and technologies, growing recognition for the use of independent centralized core laboratories, trends toward the outsourcing of imaging services in clinical trials, realized return from the Company's marketing efforts and increased use of digital medical images in clinical trials are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of revenues due to the variability in size, scope and duration of projects, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this filing and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

## Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

### RESULTS OF OPERATIONS

Nine Months Ended June 30, 2001 and 2000  
-----

Project revenues for the nine months ended June 30, 2001 and 2000 were approximately \$6,160,000 and \$4,106,000, respectively, an increase of approximately \$2,054,000 or 50.0%. Project revenues for the nine months ended June 30, 2001 and 2000 were derived from 51 clients encompassing 97 distinct projects and 38 clients encompassing 79 distinct projects, respectively. Two clients encompassing seven projects represented approximately 32.7% of the Company's project revenues for the nine months ended June 30, 2001. For the comparable period last year, two clients encompassing six projects represented approximately 30.7% of the Company's project revenues. No other customers accounted for more than 10% of project revenues for the nine months ended June 30, 2001 and 2000. The increase in project revenues is primarily a result of the increase in the number of clients and projects for which the Company was engaged to perform services. This increase resulted primarily from the increase in the Company's sales and

-10-

marketing efforts over the past year. The Company's scope of work in both periods included medical imaging core laboratory services and image-based information management services.

Cost of revenues for the nine months ended June 30, 2001 and 2000 were comprised of professional salaries and benefits and allocated overhead. Cost of revenues for the nine months ended June 30, 2001 and 2000 were approximately \$3,404,000 and \$2,706,000, respectively, an increase of approximately \$698,000 or 25.8%. This increase is attributable to an increase in staffing levels required for project related tasks for the nine months ended June 30, 2001 and in anticipation of work to be performed on new contracts as compared to the same period in the prior year.

The difference between project revenues and cost of revenues may fluctuate as a percentage of project revenues based on the utilization of staff and the mix of services provided by the Company to its clients during the comparable periods. The increase in this percentage difference for the nine months ended June 30, 2001 from the comparable period in fiscal 2000 resulted from a higher increase in project revenues as compared to a lower increase in project related costs.

General and administrative expenses for each of the nine months ended June 30, 2001 and 2000 consisted primarily of professional salaries and benefits, depreciation and amortization, professional and consulting services, office rent and corporate insurance. General and administrative expenses were approximately \$1,115,000 for the nine months ended June 30, 2001 and approximately \$964,000 for the nine months ended June 30, 2000. The increase during the nine months ended June 30, 2001 of approximately \$151,000, or 15.7%, from the corresponding fiscal 2000 period, is primarily attributable to more professional services associated with general corporate matters.

Sales and marketing expenses for each of the nine months ended June 30, 2001 and 2000 were comprised of direct sales and marketing costs, professional salaries and benefits and allocated overhead. Sales and marketing expenses were approximately \$1,272,000 for the nine months ended June 30, 2001 and approximately \$1,139,000 for the nine months ended June 30, 2000. The increase

## Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

during the nine months ended June 30, 2001 of approximately \$133,000, or 11.7%, from the corresponding fiscal 2000 period, resulted primarily from expenses associated with increased marketing efforts and increased attendance at additional conferences.

Total cost and expenses for each of the nine months ended June 30, 2001 and 2000 consisted primarily of cost of revenues, general and administrative expenses and sales and marketing expenses. The Company's cost and expenses were approximately \$5,791,000 for the nine months ended June 30, 2001 and approximately \$4,808,000 for the nine months ended June 30, 2000. Such increase of approximately \$983,000, or 20.4%, is due primarily to an increase in staffing levels required to support an increase in revenues along with an increase in the Company's sales and marketing efforts and an increase in professional services associated with general corporate matters.

-11-

Net interest expense of approximately \$17,000 for the nine months ended June 30, 2001, resulted from interest expense incurred in connection with equipment lease obligations offset in part by interest earned on cash balances. Net interest expense of approximately \$55,000 for the nine months ended June 30, 2000 resulted from interest expense incurred in the assignment of accounts receivable and interest expense incurred in connection with equipment lease obligations.

The Company's net income for the nine months ended June 30, 2001 was approximately \$352,000, while the Company had net loss of approximately \$757,000 for the nine months ended June 30, 2000. The Company's net income for the nine months ended June 30, 2001 was attributable primarily to increased revenues associated with an increase in the number of clients and projects for which the Company was engaged to perform services.

### Three Months Ended June 30, 2001 and 2000

-----

Project revenues for the quarters ended June 30, 2001 ("Third Quarter of Fiscal 2001") and 2000 ("Third Quarter of Fiscal 2000") were approximately \$2,253,000 and \$1,565,000, respectively, an increase of approximately \$688,000 or 44.0%. The increase in project revenues is primarily a result of the increase in the Company's sales and marketing efforts over the past year. Project revenues for the Third Quarter of Fiscal 2001 and Fiscal 2000 were derived from 40 clients encompassing 75 distinct projects and 33 clients encompassing 60 distinct projects, respectively. Two clients encompassing six projects represented approximately 31.2% of the Company's project revenues for the three months ended June 30, 2001. For the comparable period last year, two clients encompassing five projects represented approximately 39.5% of the Company's project revenues. No other customers accounted for more than 10% of project revenues in each of the Third Quarter of Fiscal 2001 and Fiscal 2000. The Company's scope of work in both periods included medical imaging core laboratory services and image-based information management services.

Cost of revenues for each of the Third Quarter of Fiscal 2001 and Fiscal 2000 were comprised of professional salaries and benefits and allocated overhead. Cost of revenues for the Third Quarter of Fiscal 2001 and Fiscal 2000 were approximately \$1,367,000 and \$1,053,000, respectively, an increase of approximately \$314,000 or 29.8%. This increase is attributable to an increase in staffing levels required for project related tasks for the Third Quarter of Fiscal 2001 and in anticipation of work to be performed on new contracts as compared to the Third Quarter of Fiscal 2000.

## Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

The difference between project revenues and cost of revenues may fluctuate as a percentage of project revenues based on the utilization of staff and the mix of services provided by the Company to its clients during the comparable periods. The increase in this percentage difference for the Third Quarter of Fiscal 2001 from the Third Quarter of Fiscal 2000 resulted from a higher increase in project revenues as compared to a lower increase in project related costs.

-12-

General and administrative expenses for each of the Third Quarter of Fiscal 2001 and Fiscal 2000 consisted primarily of professional salaries and benefits, depreciation and amortization, professional and consulting services, office rent and corporate insurance. General and administrative expenses were approximately \$331,000 for the Third Quarter of Fiscal 2001 and approximately \$343,000 for the Third Quarter of Fiscal 2000. The decrease of approximately \$12,000, or 3.5%, is primarily attributable to less professional services associated with general corporate matters.

Sales and marketing expenses for each of the Third Quarter of Fiscal 2001 and Fiscal 2000 were comprised of direct sales and marketing costs, professional salaries and benefits and allocated overhead. Sales and marketing expenses were approximately \$467,000 for the Third Quarter of Fiscal 2001 and approximately \$442,000 for the Third Quarter of Fiscal 2000. The increase during Third Quarter of Fiscal 2001 of approximately \$25,000, or 5.7%, from the Third Quarter of Fiscal 2000, resulted primarily from expenses associated with increased marketing efforts and increased attendance at additional conferences.

Total cost and expenses for each of the Third Quarter of Fiscal 2001 and Fiscal 2000 consisted primarily of cost of revenues, general and administrative expenses and sales and marketing expenses. The Company's cost and expenses were approximately \$2,164,000 in the Third Quarter of Fiscal 2001 and approximately \$1,838,000 for the Third Quarter of Fiscal 2000. Such increase of approximately \$326,000, or 17.7%, is primarily due to an increase in staffing levels required for project related tasks and an increase in the Company's sales and marketing efforts offset by a decrease in professional services associated with general corporate matters.

Net interest expense of approximately \$8,000 during the Third Quarter of Fiscal 2001, resulted from interest expense in connection with equipment lease obligations offset in part by interest earned on cash balances. Net interest expense of approximately \$34,000 for the Third Quarter of Fiscal 2000 resulted from interest expense incurred in the assignment of accounts receivable and interest expense incurred in conjunction with equipment lease obligations.

The Company's net income for the Third Quarter of Fiscal 2001 was approximately \$80,000, while the Company had a net loss of approximately \$307,000 for the Third Quarter of 2000. The Company's net income for the Third Quarter of Fiscal 2001 was attributable primarily to increased revenues associated with an increase in the number of clients and projects for which the Company was engaged to perform services.

-13-

## Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

### LIQUIDITY AND CAPITAL RESOURCES

At June 30, 2001, the Company had cash and cash equivalents of approximately \$147,000. Working capital at June 30, 2001 was approximately \$393,000.

Net cash used in operating activities for the nine months ended June 30, 2001 was approximately \$55,000 and resulted primarily from net income of approximately \$352,000, depreciation and amortization expense of approximately \$398,000 and an increase in accounts payable of approximately \$202,000, offset by an increase in accounts receivable of approximately \$787,000 and a decrease in deferred revenue of approximately \$109,000.

For the nine months ended June 30, 2001, the Company invested approximately \$194,000 in capital and leasehold improvements. The Company currently anticipates that capital expenditures for the remainder of fiscal 2001 will be approximately \$50,000. These expenditures represent additional upgrades in the Company's networking, data storage and core laboratory capabilities along with similar capital requirements for its European operations.

In December 2000, the Company paid to the holders of its Series A Convertible Preferred Stock, \$.00025 par value per share (the "Series A Stock"), an aggregate amount of \$20,000, which amount represented accrued cumulative dividends for the period from July 1, 2000 through and including December 31, 2000. On January 2, 2001, all outstanding shares of Series A Stock were converted into shares of common stock, \$.00025 par value per share (the "Common Stock"), and, therefore, the Company is not obligated to make any future dividend payments on the Series A Stock.

During the nine months ended June 30, 2001, the Company did not assign any accounts receivables under the accounts receivable financing agreement with Silicon Valley Bank (the "Bank"). At June 30, 2001, the Company had \$0 borrowings with the Bank. In July 2001, the Company assigned accounts receivable of approximately \$212,000 to the Bank. At July 31, 2001, the Company had a payable balance of approximately \$170,000 to the Bank.

In August 1999, the Company entered into an agreement with the Bank for a revolving line of credit of up to \$500,000 collateralized by the Company's assets. Interest is payable at 1.50% over the bank's prime rate of interest. The agreement requires the Company, among other things, to maintain minimum levels of tangible net worth and certain minimum financial ratios. In October 1999, the Bank notified the Company that it would not make any advances under the existing line of credit until the Company provides sufficient evidence satisfactory to the Bank of an improvement in the Company's operating, financial and liquidity position. At such time, the Bank may consider permitting further advances pursuant to the loan agreement.

During May and June of 2001, the Company issued an aggregate of 66,667 shares of its restricted Common Stock to Investment Partners of America, L.P. ("IPA") and its affiliate in connection with the exercise of 66,667 Class C Warrants (the "Class C Warrants") to purchase

-14-

shares of Common Stock of the Company previously issued to IPA on June 26, 1996. The Class C Warrants had an exercise price equal to \$.63 per share at the time of exercise, and the Company received \$42,000 as proceeds for the exercise of such warrants by IPA and its affiliate.

## Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

The Company anticipates that its cash and cash equivalents of \$147,479 as of June 30, 2001, together with anticipated cash from operations and its accounts receivable financing agreement with the Bank, will be sufficient to fund current working capital needs and capital requirements for at least the next twelve months. There can be no assurance, however, that the Company's operating results will achieve profitability on an annual basis in the near future. The Company's past history of operating losses and together with the risks associated with the Company's ability to gain new client contracts, the variability of the timing of payments on existing client contracts and other changes in the Company's operating assets and liabilities, may have a material adverse affect on the Company's future liquidity. In connection therewith, the Company may need to raise additional capital in the foreseeable future from equity or debt sources in order to implement its business, sales or marketing plans, take advantage of unanticipated opportunities (such as more rapid expansion, acquisitions of complementary businesses or the development of new services), to react to unforeseen difficulties (such as the decrease in the demand for the Company's services or the timing of revenues due to a variety of factors previously discussed) or to otherwise respond to unanticipated competitive pressures. There can be no assurance that additional financing will be available, if at all, on terms acceptable to the Company.

The Company's 2001 operating plans contain assumptions regarding revenue and expenses. The achievement of the operating plan depends heavily on the timing of work performed by the Company on existing projects and the ability of the Company to gain and perform work on new projects. Project cancellation, or delays in the timing of work performed by the Company on existing projects or the inability of the Company to gain and perform work on new projects could have an adverse impact on the Company's ability to execute its operating plan and maintain adequate cash flow. In the event actual results do not meet the operating plan, the Company's management believes it could execute contingency plans to mitigate such effects. Such plans include additional financing, to the extent available, through the accounts receivable financing agreement discussed above. In addition, in November 2000, the members of the Board of Directors of the Company, in their individual capacities, committed up to an aggregate amount totaling \$100,000 in the form of a short-term loan, through October 1, 2001, if needed by the Company. Considering the cash on hand and based on the achievement of the operating plan and management's actions taken to date, management believes it has the ability to continue to generate sufficient cash to satisfy its operating requirements in the normal course of business for the next 12 months. However, no assurance can be given that sufficient cash will be generated from operations. The Company's cash balance was approximately \$147,000 and \$349,000 as of June 30, 2001 and July 31, 2001, respectively.

-15-

### PART II. OTHER INFORMATION.

#### ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS.

During May and June of 2001, the Company issued an aggregate of 66,667 shares of its restricted Common Stock to IPA and its affiliate in connection with the exercise of 66,667 Class C Warrants to purchase shares of Common Stock of the Company previously issued to IPA on June 26, 1996. The Class C Warrants had an exercise price equal to \$.63 per share at the time of exercise, and the Company received \$42,000 as proceeds for the exercise of such warrants by IPA and its affiliate. The Company believes that the issuance of Common Stock in connection with the exercise of the Class C Warrants held by IPA was exempt from



## Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

registration under Section 4(2) of the Securities Act of 1933, as amended. The purchaser was an accredited investor (as defined in Rule 501 promulgated by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended), had adequate access to information about the Company and the purchaser acquired the securities for investment only and not with a view to distribution.

### ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

- (a) Exhibits.
  - 3.1 Amended and Restated Bylaws of the Company.
- (b) Reports on Form 8-K.
  - None.

-16-

### SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-IMAGING TECHNOLOGIES, INC.

DATE: August 14, 2001

By: /s/ Mark L. Weinstein

-----  
Mark L. Weinstein, President, Chief  
Executive Officer and Chief Financial  
Officer  
(Principal Executive Officer and Principal  
Financial Officer)

DATE: August 14, 2001

By: /s/ Maria T. Kraus

-----  
Maria T. Kraus, Controller  
(Principal Accounting Officer)